Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; a… Read more
Klaria Pharma Holding AB (KLAR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.706x
Based on the latest financial reports, Klaria Pharma Holding AB (KLAR) has a cash flow conversion efficiency ratio of 0.706x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.74 Million) by net assets (Skr-3.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Klaria Pharma Holding AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Klaria Pharma Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Klaria Pharma Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Klaria Pharma Holding AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VARIOUS EATERIES LS -01
F:63U
|
N/A |
|
Laser Photonics Corporation Common Stock
NASDAQ:LASE
|
0.186x |
|
Essar Shipping Limited
NSE:ESSARSHPNG
|
-0.003x |
|
SAN-EL Muhendislik Elektrik Taahhut Sanayi ve Ticaret AS
IS:SANEL
|
-0.255x |
|
DIGITAL WORKFORCE SRV.EO1
F:DQ4
|
N/A |
|
PREDATOR OIL A.GAS HLDGS
F:1EM
|
N/A |
|
Il Sung Const
KO:013360
|
0.215x |
|
Wentel Engineering Holdings Berhad
KLSE:0298
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Klaria Pharma Holding AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Klaria Pharma Holding AB from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-3.88 Million | Skr-35.04 Million | 9.032x | +350.12% |
| 2024-12-31 | Skr3.31 Million | Skr-11.94 Million | -3.611x | -1539.91% |
| 2023-12-31 | Skr41.13 Million | Skr-9.06 Million | -0.220x | +66.31% |
| 2022-12-31 | Skr76.08 Million | Skr-49.73 Million | -0.654x | -82.97% |
| 2021-12-31 | Skr69.42 Million | Skr-24.80 Million | -0.357x | -10.92% |
| 2020-12-31 | Skr109.59 Million | Skr-35.30 Million | -0.322x | -78.73% |
| 2019-12-31 | Skr82.11 Million | Skr-14.80 Million | -0.180x | -86.99% |
| 2018-12-31 | Skr94.70 Million | Skr-9.13 Million | -0.096x | -22.67% |
| 2017-12-31 | Skr153.52 Million | Skr-12.06 Million | -0.079x | +12.65% |
| 2016-12-31 | Skr160.04 Million | Skr-14.39 Million | -0.090x | -254.52% |
| 2015-12-31 | Skr174.59 Million | Skr-4.43 Million | -0.025x | -- |